Valeritas (NSDQ:VLRX) said today that cut its debt load by $25 million in a refinancing move and released its third-quarter preliminary results, sending its share price up on Wall Street in early trading. The terms of refi saw the exchange of $25.0 million in senior debt owned by CR Group and another creditor for new Series […]
Valeritas touts h-Patch CBD study
Valeritas (NSDQ:VLRX) today announced positive results from its preclinical pharmacokinetic study of cannabidiol subcutaneous infusion. The study focused on delivering cannabidiol (CBD) through subcutaneous infusion through the company’s h-Patch Wearable Device. The results were presented at the CannMed Conference in Pasadena, Calif. Results from the study showed rapid and robust absorption and distribution of 40mg of […]
Valeritas touts study results
Valeritas (NSDQ:VLRX) today announced the results of a study that showed patients using its V-Go wearable insulin delivery device needed less insulin, had lower A1c levels and reduced diabetes-related medication cost compared with patients using multiple daily injection (MDI) therapy. The retrospective study by the Bridgewater, N.J.-based company used information from the HealthCore Integrated Research Database (HIRD). […]
ADA 2019: Hybrid closed-loop devices take center stage
The American Diabetes Association’s 79th Scientific Sessions is a five-day conference where researchers and healthcare professionals share the latest in diabetes research. More than 180 sessions and over 2,000 research presentations took place during the meeting on June 7-11 in San Francisco. During the meeting, diabetes experts shared data and research from clinical trials. Here are four […]
Valeritas touts ADA’s inclusion of patch-like insulin delivery devices in diabetes management guidelines
Valeritas (NSDQ:VLRX) said today that the American Diabetes Association has endorsed the use of “disposable patch-like devices” for insulin delivery, which includes its V-Go wearable insulin delivery device. The Bridgewater, N.J.-based company said that the endorsement was made as part of the the ADA’s annual Standards of Medical Care for 2019, published in the journal Diabetes […]
Valeritas board approves 1-for-20 reverse split
Valeritas (NSDQ:VLRX) said today that its board of directors approved a 1-for-20 reverse split of its common stock. Through the move, the Bridgewater, N.J.-based company said that each owner of its common stock will receive a single share for every 20 shares they previously held. Fractional shares as a result of the split will be settled […]
Valeritas shares fall despite Street-topping Q1 sales
Shares in Valeritas (NSDQ:VLRX) are down more than 15% in after-hours trading despite the medtech firm releasing first quarter 2019 earnings that beat sales expectations and met loss-per-share consensus from Wall Street analysts. The Bridgewater, N.J.-based company posted losses of approximately $14.7 million, or 15¢ per share, on sales of $6.4 million for the three months […]
Valeritas touts reduced A1c, insulin use in V-Go insulin delivery study
Valeritas (NSDQ:VLRX) today released results from the VERDICT study of its V-Go wearable insulin delivery device, touting improved A1c levels with less insulin. Data in the study came from a retrospective analysis of 139 patients with type 2 diabetes using the V-Go device, the Bridgewater, N.J.-based company said. Read the whole story on our sister site, […]
Valeritas inks Israeli distro deal with Tritech Biomed
Valeritas (NSDQ:VLRX) said today that it inked an exclusive distribution deal with Tritech Biomed to commercialize its V-Go wearable insulin delivery device designed for patients with Type 2 diabetes in Israel. Through the deal, the Bridgewater, N.J.-based company said that Tritech Biomed will have rights to promote, market and sell the V-Go system to diabetes clinics […]
Valeritas posts mixed Q4 results
Valeritas (NSDQ:VLRX) posted its fourth-quarter and full-year financial results today, missing earnings estimates but topping revenue expectations on Wall Street. The Bridgewater, N.J.-based company posted a net loss of -$11.9 million on sales of $6.89 million for the three months ended Dec. 31, for sales growth of 19% compared with the same period last year. Get […]
Valeritas’ V-Go nabs preferred status on OptumRx formularies
Valeritas (NSDQ:VLRX) said today that its wearable insulin delivery device, V-Go, won preferred status on the OptumRx formulary. The Bridgewater, N.J.-based company’s device is designed for people with Type 2 diabetes. The V-Go product is worn like a patch and delivers a preset basal rate of insulin over the course of 24 hours. The device can […]
- 1
- 2
- 3
- …
- 6
- Next Page »
MassDevice Network
@MassDevice
LinkedIn
YouTube